Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless
Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has restructured its warrant agreement with its largest warrant holder. Under the new agreement, 100,000 warrants will be exercised for cash, while the remaining 200,000 warrants will be exercised cashlessly.
The restructuring results in two key outcomes: 1) A reduction in share dilution, with total new shares decreasing from ~300,000 to ~130,000-150,000, and 2) A reduced cash inflow of $1.2 million instead of the original $3.8 million. Management will discuss this transaction during their upcoming quarterly shareholder call around August 15th, 2025.
Precipio (NASDAQ: PRPO), un'azienda specializzata in diagnostica oncologica, ha ristrutturato il proprio accordo sui warrant con il suo maggiore detentore. Secondo il nuovo accordo, 100.000 warrant saranno esercitati con pagamento in contanti, mentre i restanti 200.000 warrant saranno esercitati senza esborso di denaro.
La ristrutturazione comporta due risultati principali: 1) una riduzione della diluizione delle azioni, con il totale delle nuove azioni che passa da circa 300.000 a circa 130.000-150.000, e 2) un flusso di cassa ridotto a 1,2 milioni di dollari invece degli originari 3,8 milioni di dollari. La direzione discuter脿 questa operazione durante la prossima chiamata trimestrale con gli azionisti prevista intorno al 15 agosto 2025.
Precipio (NASDAQ: PRPO), una empresa especializada en diagn贸stico oncol贸gico, ha reestructurado su acuerdo de warrants con su mayor tenedor. Seg煤n el nuevo acuerdo, 100,000 warrants se ejercer谩n con pago en efectivo, mientras que los 200,000 warrants restantes se ejercer谩n sin desembolso de efectivo.
La reestructuraci贸n resulta en dos efectos clave: 1) una reducci贸n en la diluci贸n de acciones, con el total de nuevas acciones disminuyendo de aproximadamente 300,000 a entre 130,000 y 150,000, y 2) una entrada de efectivo reducida a 1.2 millones de d贸lares en lugar de los 3.8 millones de d贸lares originales. La direcci贸n discutir谩 esta transacci贸n durante su pr贸xima llamada trimestral con los accionistas alrededor del 15 de agosto de 2025.
Precipio (NASDAQ: PRPO)電� 鞎� 歆勲嫧 鞝勲 須岇偓搿�, 斓滊寑 鞗岆煱韸� 氤挫湢鞛愳檧鞚� 鞗岆煱韸� 瓿勳暯鞚� 鞛惮靹表枅鞀惦媹雼�. 靸� 瓿勳暯鞐� 霐半澕 100,000 鞗岆煱韸�電� 順勱笀鞙茧 頄夓偓霅橂┌, 雮橂ǜ歆� 200,000 鞗岆煱韸�電� 氍错槃旮� 氚╈嫕鞙茧 頄夓偓霅╇媹雼�.
鞚措矆 鞛惮靹膘潣 欤检殧 瓴瓣臣電� 霊� 臧�歆�鞛呺媹雼�: 1) 欤检嫕 頋劃鞚� 臧愳唽頃橃棳 鞁犼窚 氚滍枆 欤检嫕 靾橁皜 鞎� 300,000欤检棎靹� 鞎� 130,000~150,000欤茧 欷勳柎霌れ棃瓿�, 2) 順勱笀 鞙犾瀰鞎§澊 鞗愲灅鞚� 380毵� 雼煬鞐愳劀 120毵� 雼煬搿� 臧愳唽頄堨姷雼堧嫟. 瓴届榿歆勳潃 2025雲� 8鞗� 15鞚缄步 鞓堨爼霅� 攵勱赴 欤检＜ 鞝勴檾 須岇潣鞐愳劀 鞚� 瓯半灅鞐� 雽�頃� 雲检潣頃� 鞓堨爼鞛呺媹雼�.
Precipio (NASDAQ : PRPO), une entreprise sp茅cialis茅e dans le diagnostic du cancer, a restructur茅 son accord de bons de souscription avec son principal d茅tenteur. Selon le nouvel accord, 100 000 bons seront exerc茅s contre paiement en esp猫ces, tandis que les 200 000 bons restants seront exerc茅s sans d茅caissement.
Cette restructuration entra卯ne deux cons茅quences majeures : 1) une r茅duction de la dilution des actions, le nombre total de nouvelles actions passant d'environ 300 000 脿 environ 130 000-150 000, et 2) une entr茅e de tr茅sorerie r茅duite 脿 1,2 million de dollars au lieu des 3,8 millions de dollars initialement pr茅vus. La direction discutera de cette op茅ration lors de la prochaine conf茅rence trimestrielle des actionnaires pr茅vue autour du 15 ao没t 2025.
Precipio (NASDAQ: PRPO), ein auf Krebsdiagnostik spezialisiertes Unternehmen, hat seine Optionsscheinevereinbarung mit dem gr枚脽ten Optionsscheininhaber neu strukturiert. Im Rahmen der neuen Vereinbarung werden 100.000 Optionsscheine gegen Barzahlung ausge眉bt, w盲hrend die verbleibenden 200.000 Optionsscheine ohne Barausgleich ausge眉bt werden.
Die Umstrukturierung f眉hrt zu zwei wesentlichen Ergebnissen: 1) Eine Verringerung der Aktienverw盲sserung, wobei die Gesamtzahl der neuen Aktien von ca. 300.000 auf etwa 130.000-150.000 sinkt, und 2) Ein reduzierter Bargeldzufluss von 1,2 Millionen US-Dollar statt urspr眉nglich 3,8 Millionen US-Dollar. Das Management wird diese Transaktion w盲hrend der bevorstehenden viertelj盲hrlichen Hauptversammlung etwa am 15. August 2025 别谤濒盲耻迟别谤苍.
- Reduced share dilution from ~300,000 to ~130,000-150,000 shares
- Immediate cash inflow of $1.2 million
- Reduced cash proceeds from $3.8M to $1.2M, representing a $2.6M decrease
- Warrant restructuring indicates potential challenges in executing original warrant terms
NEW HAVEN, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company听听) has entered into an agreement with its largest warrant holder, amending the existing structure from cash exercise of warrants, to a revised structure whereby 100,000 warrants (approximately 鈪�) shall be exercised with cash, and the remainder (approximately 200,000 warrants) to be exercised in a cashless manner.
The transaction accomplishes two things:
- Reducing the number of shares that will be added to the Company鈥檚 outstanding shares from ~300,000 to between ~130,000-150,000 (subject to the share price upon warrant exercise).
- Receiving ~
$1.2M in cash inflow.
This amendment reduces the cash proceeds received to ~
Management will provide further comments on this transaction in its upcoming quarterly shareholder call, to take place on or around August 15th, 2025.
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio鈥檚 reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at or follow Precipio on X (formerly Twitter) () and (Precipio) and on . Investors and others should note that we communicate with our investors and the public using our company website (), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains 鈥渇orward-looking statements鈥� within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management鈥檚 estimates, beliefs, assumptions and projections. Words such as 鈥渃ould,鈥� 鈥渕ay,鈥� 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渨ill,鈥� 鈥渢argets,鈥� 鈥済oals,鈥� 鈥減rojects,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渂elieves,鈥� 鈥渟eeks,鈥� 鈥渆stimates,鈥� 鈥減redicts,鈥� and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management鈥檚 current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption 鈥淩isk Factors鈥� in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management鈥檚 estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Inquiries:听 [email protected]听 +1-203-787-7888 Ext. 523
FAQ
What changes did Precipio (PRPO) make to its warrant agreement in July 2025?
How many new shares will be issued under Precipio's revised warrant agreement?
How much cash will Precipio (PRPO) receive from the warrant exercise?
When will Precipio management discuss the warrant restructuring?
